Pierini Stefano, Perales-Linares Renzo, Uribe-Herranz Mireia, Pol Jonathan G, Zitvogel Laurence, Kroemer Guido, Facciabene Andrea, Galluzzi Lorenzo
Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Ovarian Cancer Research Center (OCRC), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Oncoimmunology. 2017 Nov 20;6(12):e1398878. doi: 10.1080/2162402X.2017.1398878. eCollection 2017.
DNA-based vaccination is a promising approach to cancer immunotherapy. DNA-based vaccines specific for tumor-associated antigens (TAAs) are indeed relatively simple to produce, cost-efficient and well tolerated. However, the clinical efficacy of DNA-based vaccines for cancer therapy is considerably limited by central and peripheral tolerance. During the past decade, considerable efforts have been devoted to the development and characterization of novel DNA-based vaccines that would circumvent this obstacle. In this setting, particular attention has been dedicated to the route of administration, expression of modified TAAs, co-expression of immunostimulatory molecules, and co-delivery of immune checkpoint blockers. Here, we review preclinical and clinical progress on DNA-based vaccines for cancer therapy.
基于DNA的疫苗接种是一种很有前景的癌症免疫治疗方法。针对肿瘤相关抗原（TAA）的基于DNA的疫苗确实相对易于生产、成本效益高且耐受性良好。然而，基于DNA的癌症治疗疫苗的临床疗效受到中枢和外周免疫耐受的极大限制。在过去十年中，人们付出了巨大努力来开发和表征能够克服这一障碍的新型基于DNA的疫苗。在这种情况下，人们特别关注给药途径、修饰TAA的表达、免疫刺激分子的共表达以及免疫检查点阻断剂的共同递送。在此，我们综述基于DNA的癌症治疗疫苗的临床前和临床进展。
